drugset / Trial / NCT01267955

Vismodegib in Treating Patients With Advanced Chondrosarcomas

NCT01267955

Phase 2 Active not recruiting 45 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well vismodegib works in treating patients with chondrosarcomas that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Timeline

Start
2010-12-21
Primary completion
2018-06-30
Completion
2026-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Vismodegib Small molecule 150 mg Oral